A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

Condition studied

Non-small Cell Lung Cancer

Investigational medicinal product(s)

Every trial of Mycophenolate Mofetil, Infliximab, Rilvegostomig and Pemetrexed across our registers →

Eligibility

Primary endpoint

The safety and tolerability of immunotherapy with or without other anticancer drugs in participants with unresectable Stage III NSCLC will be assessed.

Endpoint detail

PFS is defined as time from the date of treatment assignment/randomization or Cycle 1 Day 1 (as applicable, depending on the design of the relevant substudy) until radiological progression per RECIST 1.1 or death due to any cause (in the absence of progression)., ORR is defined as the proportion of participants who have a CR or PR, "XXX" per RECIST 1.1 for induction therapy or overall., Concentration of immunotherapy in serum., Presence of anti-drug antibodies (ADAs), positive or negative and titers